HK-listed entities launch healthcare investment platform
HONG KONG: Hong Kong-listed cardiovascular medical devices developer Venus Medtech, Asia-focused private equity firm DCP Capital, and Chinese venture capital firm Qiming Venture Partners have inked an agreement to launch a healthcare investment platform.
The new healthcare investment platform, named “Ascendum Capital Partners”, will primarily invest in innovative medical device companies in the global cardiovascular and lung disease treatment space, according to a statement on Thursday.
By leveraging Venus Medtech’s industry resources and the investment expertise of DCP Capital and Qiming Venture Partners, Ascendum aims to accelerate the R&D and commercialization of global medical device technologies, and support medtech innovation and medtech companies in China.
The venture will be led by Serena Shao, a former healthcare research analyst at Credit Suisse, and supported by a professional team with experiences in investing and operating global medical device companies.
According to the Credit Suisse website – which has not indicated her departure – Shao, based in Hong Kong with over 15 years of experience in the healthcare and financial industries, is the head of Credit Suisse, China healthcare research.
Shao joined Credit Suisse from CLSA, where she was also the head of China healthcare research. She previously worked in BoAML as an equity analyst, and Vertex Pharmaceutical as a research scientist working on the treatment of Heptitas C, based in Boston, U.S.
“Ascendum marks the beginning for our new adventure to shape and navigate in the global innovative medical device industry”, said Eric Zi, co-founder and CEO of Venus Medtech, in the statement.
“We deeply trust Qiming Venture Partners and DCP Capital as business partners. Through multiple years of partnership, both investors have provided us with valuable expertise on operations, M&A and capital markets. We are thrilled to work with them again”, said Zi.
Qiming Venture Partners and DCP Capital, along with other top-notch investors like Sequoia Capital China and Goldman Sachs, were among Venus Medtech backers before the company IPO offering in Hong Kong.
Hangzhou-based Venus Medtech was founded in 2009 to operate as a cardiovascular medical device company in China and a developer of transcatheter aortic valve replacement (TAVR), which is a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly.
Its self-developed VenusA-Valve, approved by China National Medical Products Administration in April 2017, was the first TAVR product approved and commercialized in the country. According to Frost & Sullivan, Venus Medtech had a 79.3 per cent market share in China by implantation volume of TAVR products in 2018.
The company has built a product pipeline covering all four heart valves, intellectual property portfolio with 193 issued patents and 196 patent applications as of November 18, 2019.
Backed by cornerstone investors like Asia-focused private equity firm Hillhouse Capital and Singaporean sovereign wealth fund GIC, Venus Medtechraised HK$2.41 billion ($308 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX) in December 2019.






